Author

A. C. Jain

Primary ORCID profile (0000-0003-3559-4761 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

A. C. JAINiD1 paper · University of North Carolina at Chapel Hill

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

A. Malovannaya· 1 shared B. Cuglievan· 1 shared C. D. DiNardo· 1 shared C. E. Birdwell· 1 shared C. P. Mill· 1 shared D. Hammond· 1 shared H. Hou· 1 shared J. A. Davis· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Malovannaya

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor

W. C. Fiskus, J. Piel, M. Collins, M. Hentemann, B. Cuglievan, C. P. Mill, C. E. Birdwell, K. Das, J. A. Davis, H. Hou, A. C. Jain, A. Malovannaya, T. M. Kadia, N. Daver, K. Sasaki, , K. N. Bhalla

This study shows that FHD-286, a BRG1/BRM inhibitor, reduces AML burden and improves survival when combined with Menin or BET inhibitors in xenograft models of AML with MLL1r or mtNPM1.

bioRxiv · Sep 28, 2023Cancer Biology